UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Bioavailability and safety of diazepam intranasal solution compared to oral and rectal diazepam in healthy volunteers

Epilepsia (Copenhagen), 2020-03, Vol.61 (3), p.455-464

2020

Volltextzugriff (PDF)

Evaluation of Pharmacokinetics and Dose Proportionality of Diazepam After Intranasal Administration of NRL‐1 to Healthy Volunteers

Clinical pharmacology in drug development, 2020-08, Vol.9 (6), p.719-727

2020

Volltextzugriff (PDF)

Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections

Drug metabolism and disposition, 2009-06, Vol.37 (6), p.1164-1171

2009

Volltextzugriff (PDF)

S860 Efficacy of the Melanocortin Receptor Agonist PL8177 as a Potential Therapy for Gastrointestinal (GI) Inflammatory Diseases

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e621-e622

2022

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic comparison of epinephrine, administered intranasally and intramuscularly: An integrated analysis

Annals of allergy, asthma, & immunology, 2023-04, Vol.130 (4), p.508

2023

Volltextzugriff (PDF)

Sa1222 EFFICACY OF THE MELANOCORTIN RECEPTOR AGONIST PL8177 AS A POTENTIAL THERAPY FOR GASTROINTESTINAL (GI) INFLAMMATORY DISEASES

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-330-S-330

2023

Volltextzugriff (PDF)

Comparison of Pharmacokinetic Parameters and Intra-Blood Vessel Injection Rates Between Manual IM injection and Epinephrine Auto-Injectors

Journal of allergy and clinical immunology, 2022-02, Vol.149 (2), p.AB3-AB3

2022

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Neffy (1 mg) compared to EpiPen (0.3 mg) and Manual IM injection (0.3 mg) – an Integrated Analysis

Journal of allergy and clinical immunology, 2022-02, Vol.149 (2), p.AB3-AB3

2022

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic comparison of epinephrine, administered intranasally and intramuscularly

Annals of allergy, asthma, & immunology, 2023-04, Vol.130 (4), p.508-514.e1

2023

Volltextzugriff (PDF)

Effect of food intake on the pharmacokinetics of rivoceranib in healthy subjects

Fundamental & clinical pharmacology, 2022-02, Vol.36 (1), p.171-181

2022

Volltextzugriff (PDF)

Absence of ethnic difference on single‐dose pharmacokinetics of rivoceranib between healthy male Caucasian, Japanese, and Chinese subjects

Fundamental & clinical pharmacology, 2021-04, Vol.35 (2), p.485-495

2021

Volltextzugriff (PDF)

Fr487 PHARMACOKINETIC ANALYSIS IN RATS AND DOGS AFTER ORAL DOSING OF MELANOCORTIN-1 RECEPTOR AGONIST PL8177

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.S-327-S-328

2021

Volltextzugriff (PDF)

A selective small molecule agonist of the melanocortin-1 receptor inhibits lipopolysaccharide-induced cytokine accumulation and leukocyte infiltration in mice

Journal of leukocyte biology, 2006-10, Vol.80 (4), p.897-904

2006

Volltextzugriff (PDF)

Pharmacokinetics of the Melanocortin Type 1 Receptor Agonist PL8177 After Subcutaneous Administration

Drugs in R&D, 2021-12, Vol.21 (4), p.431-443

2021

Volltextzugriff (PDF)

A phase I study to evaluate the pharmacokinetics of a new oncology nce, apatinib mesylate tablets, with and without food following single and multiple doses in healthy subjects

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e14049-e14049

2017

Volltextzugriff (PDF)

Biorelevant In Vitro Skin Permeation Testing and In Vivo Pharmacokinetic Characterization of Lidocaine from a Nonaqueous Drug-in-Matrix Topical System

AAPS PharmSciTech, 2021-08, Vol.22 (6), p.215-215, Article 215

2021

Volltextzugriff (PDF)

Eleven Amino Acid Glucagon-like Peptide-1 Receptor Agonists with Antidiabetic Activity

Journal of medicinal chemistry, 2009-12, Vol.52 (23), p.7788-7799

2009

Volltextzugriff (PDF)

Exploration of structure–activity relationships at the two C-terminal residues of potent 11mer Glucagon-Like Peptide-1 receptor agonist peptides via parallel synthesis

Peptides (New York, N.Y. : 1980), 2010-07, Vol.31 (7), p.1353-1360

2010

Volltextzugriff (PDF)

Exploration of structure-activity relationships at the two C-terminal residues of potent 11 mer Glucagon-Like Peptide-1 receptor agonist peptides via parallel synthesis

Peptides (New York, N.Y. : 1980), 2010, Vol.31 (7), p.1353-1360

2010

Volltextzugriff (PDF)

Design, synthesis, and structure–activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors

Bioorganic & medicinal chemistry letters, 2005-04, Vol.15 (7), p.1895-1899

2005

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(22)

Sprache

Englisch
(22)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Bioavailability and safety of diazepam intranasal solution compared to oral and rectal diazepam in healthy volunteers

Evaluation of Pharmacokinetics and Dose Proportionality of Diazepam After Intranasal Administration of NRL‐1 to Healthy Volunteers

Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections

S860 Efficacy of the Melanocortin Receptor Agonist PL8177 as a Potential Therapy for Gastrointestinal (GI) Inflammatory Diseases

Pharmacokinetic and pharmacodynamic comparison of epinephrine, administered intranasally and intramuscularly: An integrated analysis

Sa1222 EFFICACY OF THE MELANOCORTIN RECEPTOR AGONIST PL8177 AS A POTENTIAL THERAPY FOR GASTROINTESTINAL (GI) INFLAMMATORY DISEASES

Comparison of Pharmacokinetic Parameters and Intra-Blood Vessel Injection Rates Between Manual IM injection and Epinephrine Auto-Injectors

Pharmacokinetics and Pharmacodynamics of Neffy (1 mg) compared to EpiPen (0.3 mg) and Manual IM injection (0.3 mg) – an Integrated Analysis

Pharmacokinetic and pharmacodynamic comparison of epinephrine, administered intranasally and intramuscularly

Effect of food intake on the pharmacokinetics of rivoceranib in healthy subjects

Absence of ethnic difference on single‐dose pharmacokinetics of rivoceranib between healthy male Caucasian, Japanese, and Chinese subjects

Fr487 PHARMACOKINETIC ANALYSIS IN RATS AND DOGS AFTER ORAL DOSING OF MELANOCORTIN-1 RECEPTOR AGONIST PL8177

A selective small molecule agonist of the melanocortin-1 receptor inhibits lipopolysaccharide-induced cytokine accumulation and leukocyte infiltration in mice

Pharmacokinetics of the Melanocortin Type 1 Receptor Agonist PL8177 After Subcutaneous Administration

A phase I study to evaluate the pharmacokinetics of a new oncology nce, apatinib mesylate tablets, with and without food following single and multiple doses in healthy subjects

Biorelevant In Vitro Skin Permeation Testing and In Vivo Pharmacokinetic Characterization of Lidocaine from a Nonaqueous Drug-in-Matrix Topical System

Eleven Amino Acid Glucagon-like Peptide-1 Receptor Agonists with Antidiabetic Activity

Biphenylsulfonamide Endothelin Receptor Antagonists. 4. Discovery of N-[[2‘-[[(4,5-Dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1‘-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), A Highly Potent and Orally Active ETA Selective Antagonist

Exploration of structure–activity relationships at the two C-terminal residues of potent 11mer Glucagon-Like Peptide-1 receptor agonist peptides via parallel synthesis

Exploration of structure-activity relationships at the two C-terminal residues of potent 11 mer Glucagon-Like Peptide-1 receptor agonist peptides via parallel synthesis

Design, synthesis, and structure–activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors

Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist

Suchergebnisse filtern